Fixed-time chlorazepate dipotassium premedication versus midazolam on demand: a randomised, controlled trial

Submission date	Recruitment status	Prospectively registered
13/12/2006	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
13/02/2007	Completed	[X] Results
Last Edited	Condition category	[] Individual participant data
26/03/2021	Surgery	

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Patrick Meybohm

Contact details

University Hospital Schleswig-Holstein Campus Kiel Schwanenweg 21 Kiel Germany 24105

_

meybohm@anaesthesie.uni-kiel.de

Additional identifiers

Protocol serial number N/A

Study information

Scientific Title

Fixed-time chlorazepate dipotassium premedication versus midazolam on demand: a randomised, controlled trial

Acronym

premedication

Study objectives

We hypothesised that:

- 1. 50 mg chlorazepate dipotassium at 10 pm evening before surgery prevent an increase of anxiety and sympatho-adrenal activity at morning of surgery sufficiently, and
- 2. A fixed-time application of chlorazepate dipotassium at 7 am morning of surgery may be superior compared to administration of midazolam 30 minutes prior to induction of anesthesia with respect to level of anxiety, sympatho-adrenal activity and conscious sedation.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The trial was approved by the local ethics committee of the University Kiel on the 3rd April 2002 (reference number: AZ 142/01).

Study design

Randomised double-blind placebo-controlled study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Premedication, Anaesthesia

Interventions

Patients were randomised to one of two groups:

1. Group CCP: at Evening Before Surgery (EBS) clorazepate dipotassium 50 mg orally (Tranxilium®; Sanofi-Aventis GmbH, Frankfurt am Main, Germany); at Morning Of Surgery (MOS) clorazepate dipotassium 25 mg orally; and before Induction of Anesthesia (AI) placebo orally 2. Group CPM: at EBS clorazepate dipotassium 50 mg orally; at MOS placebo orally; before AI midazolam 7.5 mg orally (Dormicum®; Roche, Mijdrecht, The Netherlands)

Dosages of clorazepate dipotassium in our study were based on recommendations that have been published previously.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Chlorazepate dipotassium and midazolam

Primary outcome(s)

- 1. Level of anxiety
- 2. Sympatho-adrenal activity (plasma levels of Adrenocorticotropic Hormone [ACTH], cortisol, norepinephrine and epinephrine)

Key secondary outcome(s))

- 1. Haemodynamic data
- 2. Oxygen saturation
- 3. Conscious sedation
- 4. Bispectral index

Completion date

01/10/2004

Eligibility

Key inclusion criteria

- 1. Patients with an American Society of Anaesthesiologists (ASA) physical status of one or two
- 2. Aged between 18 and 55 years
- 3. Weighing from 60 to 88 kg
- 4. Scheduled to undergo an elective surgical, orthopaedic or urologic procedure in general anesthesia

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Not Specified

Total final enrolment

50

Key exclusion criteria

- 1. Sleep apnoea syndrome
- 2. Pregnancy
- 3. Use of sedative, stimulant, or other medications within the previous month
- 4. The presence of neurological, renal, or hepatic disease

Date of first enrolment

Date of final enrolment 01/10/2004

Locations

Countries of recruitment

Germany

Study participating centre University Hospital Schleswig-Holstein Kiel Germany 24105

Sponsor information

Organisation

University Hospital Schleswig-Holstein (Germany)

ROR

https://ror.org/01tvm6f46

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

University Hospital Schleswig-Holstein (Germany)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output typeDetailsDate createdDate addedPeer reviewed?Patient-facing?Results article01/09/200726/03/2021YesNo